Filter By Category
Archives
Share on -
DALATAZIDE
Generic Name: DALATAZIDE
ABSTRACT -
The provided name “Dalatazide” appears to correspond to dalazatide, a synthetic ShK-derived peptide blocker of the Kv1.3 potassium channel investigated for autoimmune and inflammatory diseases. A peptide schematic is used because ordinary small-molecule structure representation is not appropriate.
DOSAGE -
- No routine clinical dosage is established for general use.
- Dose, route, injection schedule, and immune monitoring must follow clinical-trial protocol.
- Do not substitute peptide products or compounded preparations.
SIDE EEFECTS -
- Injection-site reactions, headache, nausea, fatigue, rash, or pruritus may occur.
- Immune effects, infection risk, or laboratory changes may occur depending on dose and population.
- Hypersensitivity or anti-drug antibodies are possible.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- Other immunosuppressants, biologics, vaccines, or potassium-channel-active drugs require specialist review.
- Live vaccines should be timed only with specialist direction.
- Patients should report all medicines and supplements.
PREAUTONS–
- Confirm the intended API name and peptide identity before manufacturing or documentation use.
- Monitor injection reactions, infection, immune status, and laboratory values.
- Pregnancy and lactation require specialist review.
WARNINGS –
- Anaphylaxis, serious infection, severe neurologic symptoms, or marked immune reaction requires urgent care.
- Investigational efficacy and safety are not fully established.
- Keep out of reach of children.
Share on -
. Developed by